Kintor Pharmaceutical (HKSE:09939) Accounts Payable & Accrued Expense : HK$116.49 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Accounts Payable & Accrued Expense?

Kintor Pharmaceutical's quarterly accounts payable & accrued expense declined from Dec. 2022 (HK$239.86 Mil) to Jun. 2023 (HK$184.98 Mil) and declined from Jun. 2023 (HK$184.98 Mil) to Dec. 2023 (HK$116.49 Mil).

Kintor Pharmaceutical's annual accounts payable & accrued expense declined from Dec. 2021 (HK$257.47 Mil) to Dec. 2022 (HK$239.86 Mil) and declined from Dec. 2022 (HK$239.86 Mil) to Dec. 2023 (HK$116.49 Mil).

Kintor Pharmaceutical Accounts Payable & Accrued Expense Historical Data

The historical data trend for Kintor Pharmaceutical's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Accounts Payable & Accrued Expense Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

89.02

97.99

257.47

239.86

116.49

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial						257.47	335.08	239.86	184.98	116.49

Kintor Pharmaceutical Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Kintor Pharmaceutical (HKSE:09939) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.

Executives

Tong Youzhi	2101 Beneficial owner
Kt International Investment Limited	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Tong Youzhi	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines